Linked Life Data

10598792

Source:http://linkedlifedata.com/resource/pubmed/id/10598792

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:10598792rdf:typepubmed:Citationlld:pubmed
pubmed-article:10598792lifeskim:mentionsumls-concept:C0006675lld:lifeskim
pubmed-article:10598792lifeskim:mentionsumls-concept:C0086418lld:lifeskim
pubmed-article:10598792lifeskim:mentionsumls-concept:C0007634lld:lifeskim
pubmed-article:10598792lifeskim:mentionsumls-concept:C0004114lld:lifeskim
pubmed-article:10598792lifeskim:mentionsumls-concept:C0185112lld:lifeskim
pubmed-article:10598792lifeskim:mentionsumls-concept:C2246329lld:lifeskim
pubmed-article:10598792lifeskim:mentionsumls-concept:C1704666lld:lifeskim
pubmed-article:10598792lifeskim:mentionsumls-concept:C1517892lld:lifeskim
pubmed-article:10598792lifeskim:mentionsumls-concept:C0208973lld:lifeskim
pubmed-article:10598792pubmed:issue5lld:pubmed
pubmed-article:10598792pubmed:dateCreated2000-2-7lld:pubmed
pubmed-article:10598792pubmed:abstractTextThe human U373 MG astrocytoma cell line has been widely used as a model system for the investigation of astrocyte function. The aim of this study was to establish which alpha1-adrenoceptors are present on these cells. The specific binding of [3H]prazosin to membranes of U373 MG cells (Bmax 32+/-3 fmol mg(-1) protein, Kd 0.27+/-0.03 nM) was inhibited in a monophasic manner by alpha1-antagonists that have different affinities for alpha1A-, alpha1B- and alpha1D-adrenoceptors. Estimates for pKi values were: prazosin 9.69+/-0.06, 5-methylurapidil 7.10+/-0.21; (+)-niguldipine 7.06+/-0.26; WB 4101 8.26+/-0.16; and BMY 7378 6.60+/-0.21. The specific binding of [3H]prazosin was reduced to low levels by pretreatment of cells with 10 microM chloroethylclonidine for 15 min. In the presence of 30 mM LiCl, 100 microM noradrenaline stimulated [3H]inositol phosphate accumulation by 2.1+/-0.1-fold of basal after 30-min incubation. The EC50 for the accumulation of [3H]IP1, the major product detected (85+/-2% of total [3H]IP1 + [3H]IP2 + [3H]IP3), was 0.38+/-0.05 microM. Noradrenaline-induced [3H]IP1 accumulation was also inhibited by alpha1-antagonists. Estimates for pKi values were: 5-methylurapidil 6.95+/-0.01; WB 4101 8.31+/-0.07; and BMY 7378 6.71+/-0.28. The accumulation of [3H]IP1 in response to 100 microM noradrenaline was not significantly affected by raising the extracellular Ca2+ concentration from 1.3 to 4 mM. Noradrenaline (100 microM) also produced an increase in intracellular Ca2+ (mean peak 86+/-5 nM above basal). Pretreatment with chloroethylclonidine (10 microM, 15 min) abolished noradrenaline-induced [3H]IP1 accumulation and Ca2+ mobilisation. Activation of the alpha1B-adrenoceptors by 10 microM phenylephrine increased [3H]thymidine uptake to 140+/-5% of control uptake. Taken together, these results indicate that U373 MG cells express a single class of alpha1-adrenoceptors, the alpha1B-subtype, which are coupled to phosphoinositide hydrolysis and calcium mobilisation, and which mediate a mitogenic response to alpha1-agonists.lld:pubmed
pubmed-article:10598792pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10598792pubmed:languageenglld:pubmed
pubmed-article:10598792pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10598792pubmed:citationSubsetIMlld:pubmed
pubmed-article:10598792pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10598792pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10598792pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10598792pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10598792pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10598792pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10598792pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10598792pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10598792pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10598792pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10598792pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10598792pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10598792pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10598792pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10598792pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10598792pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10598792pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10598792pubmed:statusMEDLINElld:pubmed
pubmed-article:10598792pubmed:monthNovlld:pubmed
pubmed-article:10598792pubmed:issn0028-1298lld:pubmed
pubmed-article:10598792pubmed:authorpubmed-author:YoungJ MJMlld:pubmed
pubmed-article:10598792pubmed:authorpubmed-author:Arias-Montaño...lld:pubmed
pubmed-article:10598792pubmed:authorpubmed-author:Soria-JassoL...lld:pubmed
pubmed-article:10598792pubmed:authorpubmed-author:BergerV AVAlld:pubmed
pubmed-article:10598792pubmed:issnTypePrintlld:pubmed
pubmed-article:10598792pubmed:volume360lld:pubmed
pubmed-article:10598792pubmed:ownerNLMlld:pubmed
pubmed-article:10598792pubmed:authorsCompleteYlld:pubmed
pubmed-article:10598792pubmed:pagination533-9lld:pubmed
pubmed-article:10598792pubmed:dateRevised2010-8-25lld:pubmed
pubmed-article:10598792pubmed:meshHeadingpubmed-meshheading:10598792...lld:pubmed
pubmed-article:10598792pubmed:meshHeadingpubmed-meshheading:10598792...lld:pubmed
pubmed-article:10598792pubmed:meshHeadingpubmed-meshheading:10598792...lld:pubmed
pubmed-article:10598792pubmed:meshHeadingpubmed-meshheading:10598792...lld:pubmed
pubmed-article:10598792pubmed:meshHeadingpubmed-meshheading:10598792...lld:pubmed
pubmed-article:10598792pubmed:meshHeadingpubmed-meshheading:10598792...lld:pubmed
pubmed-article:10598792pubmed:meshHeadingpubmed-meshheading:10598792...lld:pubmed
pubmed-article:10598792pubmed:meshHeadingpubmed-meshheading:10598792...lld:pubmed
pubmed-article:10598792pubmed:meshHeadingpubmed-meshheading:10598792...lld:pubmed
pubmed-article:10598792pubmed:meshHeadingpubmed-meshheading:10598792...lld:pubmed
pubmed-article:10598792pubmed:meshHeadingpubmed-meshheading:10598792...lld:pubmed
pubmed-article:10598792pubmed:meshHeadingpubmed-meshheading:10598792...lld:pubmed
pubmed-article:10598792pubmed:meshHeadingpubmed-meshheading:10598792...lld:pubmed
pubmed-article:10598792pubmed:meshHeadingpubmed-meshheading:10598792...lld:pubmed
pubmed-article:10598792pubmed:meshHeadingpubmed-meshheading:10598792...lld:pubmed
pubmed-article:10598792pubmed:meshHeadingpubmed-meshheading:10598792...lld:pubmed
pubmed-article:10598792pubmed:meshHeadingpubmed-meshheading:10598792...lld:pubmed
pubmed-article:10598792pubmed:year1999lld:pubmed
pubmed-article:10598792pubmed:articleTitleCharacterisation of alpha1B-adrenoceptors linked to inositol phosphate formation and calcium mobilisation in human astrocytoma U373 MG cells.lld:pubmed
pubmed-article:10598792pubmed:affiliationDepartamento de Fisiología, Biofísica y Neurociencias, Centro de Investigación y de Estudios Avanzados, México, DF.lld:pubmed
pubmed-article:10598792pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:10598792pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10598792lld:pubmed